Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Kivu Bioscience Inc.
University of California, San Francisco
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Alabama at Birmingham
MOMA Therapeutics
Kestrel Therapeutics, Inc.
Mersana Therapeutics
Canadian Cancer Trials Group
Corcept Therapeutics
Cancer Trials Ireland
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
National Cancer Institute (NCI)
Hoffmann-La Roche
University of British Columbia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Context Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute, Naples
Regor Pharmaceuticals Inc.
OncoC4, Inc.
Parabilis Medicines, Inc.
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
University of Florida
Compass Therapeutics
Revolution Medicines, Inc.
Bayer
AstraZeneca
University of Rochester
Eikon Therapeutics
USWM, LLC (dba US WorldMeds)
Genmab
Seagen Inc.
Fate Therapeutics